Incyte (NASDAQ:INCY) Stock Rating Lowered by William Blair

William Blair lowered shares of Incyte (NASDAQ:INCY) from an outperform rating to a market perform rating in a report issued on Tuesday morning, MarketBeat reports. William Blair also issued estimates for Incyte’s Q2 2025 earnings at $1.11 EPS, Q3 2025 earnings at $1.19 EPS, FY2025 earnings at $4.21 EPS and Q3 2026 earnings at $1.30 EPS.

A number of other brokerages have also weighed in on INCY. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. UBS Group started coverage on Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price objective for the company. Citigroup dropped their target price on Incyte from $97.00 to $88.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. StockNews.com downgraded Incyte from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company lifted their price objective on shares of Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $75.13.

Incyte Trading Up 0.4 %

NASDAQ:INCY opened at $60.58 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The business’s 50-day simple moving average is $70.78 and its 200-day simple moving average is $70.13. Incyte has a fifty-two week low of $50.35 and a fifty-two week high of $83.95. The stock has a market capitalization of $11.72 billion, a PE ratio of 224.38, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. Sell-side analysts expect that Incyte will post 4.86 earnings per share for the current fiscal year.

Insider Transactions at Incyte

In other news, EVP Sheila A. Denton sold 14,069 shares of Incyte stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the completion of the transaction, the executive vice president now directly owns 25,848 shares in the company, valued at approximately $1,914,561.36. The trade was a 35.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Steven H. Stein sold 12,352 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total value of $897,866.88. Following the completion of the sale, the executive vice president now owns 66,967 shares in the company, valued at approximately $4,867,831.23. This trade represents a 15.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,827 shares of company stock worth $3,322,618 in the last ninety days. Insiders own 17.60% of the company’s stock.

Institutional Trading of Incyte

A number of hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP increased its stake in shares of Incyte by 26.5% during the third quarter. GSA Capital Partners LLP now owns 6,453 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 1,351 shares during the period. CIBC Asset Management Inc lifted its holdings in shares of Incyte by 2.9% during the third quarter. CIBC Asset Management Inc now owns 25,303 shares of the biopharmaceutical company’s stock worth $1,673,000 after buying an additional 723 shares in the last quarter. Swiss National Bank boosted its position in shares of Incyte by 0.9% in the third quarter. Swiss National Bank now owns 483,274 shares of the biopharmaceutical company’s stock valued at $31,944,000 after acquiring an additional 4,500 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Incyte in the third quarter valued at about $186,000. Finally, Banque Cantonale Vaudoise grew its stake in shares of Incyte by 336.1% in the third quarter. Banque Cantonale Vaudoise now owns 8,730 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 6,728 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.